All In Biotech

Drug Trial Radar · NCT07254429

COMPASS - COpenhagen MenoPAuSe Study

Copenhagen Menopause Study (COMPASS): A Randomized Clinical Trial

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Oct 2, 2025

Primary completion

Dec 2027

Study completion May 2028

Sponsor

Lead sponsor
Martin Blomberg JensenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications. Estrogen therapy can help, but some women avoid it due to the increased risk of blood clots and cancer. This project will investigate whether blocking LH could offer a safe alternative to alleviate symptoms and complications of menopause since it is known from previous research that high LH levels contribute to both bone deterioration and metabolic issues. The goal is to explore new treatment options that can improve health and quality of life for women both during and after menopause. This randomized clinical trial is a single center, sponsor-investigator-initiated single-blinded 8 weeks clinical trial with four parallel groups comparing the effect of an gonadotropin releasing hormone(GnRH)-analog with placebo, and with two additional arms given estrogen or testosterone on change on bone health in postmenopausal women with moderate-to-severe symptoms.

Conditions

  • Menopausal Osteoporosis
  • Bone Markers

Interventions

  • Triptorelin 11.25 mgDrug

    Pamorelin 11.25 mg intramuscular injection once

  • Sodium Chloride 0.9%Drug

    Saline intramuscular injection once

  • Estradiol (E2)Drug

    Estreva gel 1.5 mg daily

  • TestosteroneDrug

    Tostran gel 10 mg every other day

  • Placebo gelDrug

    Placebo gel every day or every other day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in bone remodeling from baseline to week 8.Time frame: From baseline to week 8
  2. Change in bone remodeling from baseline to week 8.Time frame: From baseline to week 8
  3. Change in bone remodeling from baseline to week 8Time frame: From baseline to week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev.

    Herlev, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.